Message #48 From:
Stock News Bot Date: February 15, 2007 08:38:00 AM
OSCI News Oscient Pharmaceuticals Announces Date for Release of Fourth Quarter Financial Results
WALTHAM, Mass.--(BUSINESS WIRE)--Oscient Pharmaceuticals Corporation (Nasdaq:OSCI) will release financial results for the fourth quarter and fiscal year ended December 31, 2006 on Tuesday, February 27, 2007 prior to the opening of the U.S. financial markets. A conference call will be held at 8:30 a.m. Eastern Time with Steven Rauscher, President and CEO, and other members of Oscient’s management team. The Company announced preliminary revenue results for the fourth quarter on January 8, 2007.
What: Fourth Quarter Financial Results
When: February 27, 2007 at 8:30 am Eastern Time
How: Domestic participants can access the call by dialing 1-888-634-4009. International participants are asked to dial 1-706-634-2285. The call will also be webcast through the Company’s website at www.oscient.com.
A replay will be available two hours after the conclusion of the call until March 6, 2007. Domestic participants can access the replay by dialing 1-800-642-1687, while international participants are asked to dial 1-706-645-9291. The conference ID number for the replay is 8411143. A replay will also be available through www.oscient.com.
About Oscient Pharmaceuticals
Oscient Pharmaceuticals Corporation is a commercial-stage biopharmaceutical company marketing two FDA-approved products with its national primary care sales force. ANTARA® (fenofibrate) capsules is indicated for the adjunct treatment of hypercholesterolemia (high blood cholesterol) and hypertriglyceridemia (high triglycerides) in combination with diet. FACTIVE® (gemifloxacin mesylate) tablets is an antibiotic approved for the treatment of acute bacterial exacerbations of chronic bronchitis and community-acquired pneumonia of mild to moderate severity. Oscient also has a novel, late-stage antibiotic candidate, Ramoplanin, under investigation for the treatment of Clostridium difficile-associated disease (CDAD).
For important information regarding the safety and use of ANTARA and FACTIVE, please see the full prescribing information available at www.antararx.com and www.factive.com.
